{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Black Diamond Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"BDTX"},"Address":{"label":"Address","value":"ONE MAIN STREET,10TH FLOOR 14TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 617 252-0848"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535."},"CompanyUrl":{"label":"Company Url","value":"https://www.blackdiamondtherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brent Hatzis-Schoch","title":"Chief Operating Officer & General Counsel"},{"name":"Elizabeth Buck","title":"CSO, EVP-Discovery & Translational Sciences"},{"name":"Mark A. Velleca","title":"Chairman, President & Chief Executive Officer"},{"name":"Sergey Yurasov","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}